Abnormal Fibrinogens

Fibrinogens which have a functional defect as the result of one or more amino acid substitutions in the amino acid sequence of normal fibrinogen. Abnormalities of the fibrinogen molecule may impair any of the major steps involved in the conversion of fibrinogen into stabilized fibrin, such as cleavage of the fibrinopeptides by thrombin, polymerization and cross-linking of fibrin. The resulting dysfibrinogenemias can be clinically silent or can be associated with bleeding, thrombosis or defective wound healing.

Also Known As:

Networked: 8 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Lin, Faquan: 1 article (03/2022)
2.	Luo, Meiling: 1 article (03/2022)
3.	Wu, Yangyang: 1 article (03/2022)
4.	Xiang, Liqun: 1 article (03/2022)
5.	Yan, Jie: 1 article (03/2022)
6.	Mirshahi, Massoud: 1 article (04/2019)
7.	Mirshahi, Sam Qiumars: 1 article (04/2019)
8.	Mirshahi, Shahsoltan: 1 article (04/2019)
9.	Pritchard, Linda L: 1 article (04/2019)
10.	Soria, Claudine: 1 article (04/2019)

Related Diseases

1.	Thrombosis (Thrombus) 06/01/2015 - "Correlations between genotype and phenotype have not yet been clearly established, with the exception of some abnormal fibrinogens that severely increase the risk of thrombosis. " 07/01/1989 - "Congenital abnormalities of fibrinolysis associated with thrombosis include plasminogen deficiency, decreased endothelial generation of plasminogen activator activity, and certain abnormal fibrinogens. " 03/01/1988 - "Low levels or dysfunctional forms of antithrombin III, protein C and protein S and abnormal fibrinogens are the most frequent and well-established inherited causes for thrombosis. "
2.	Hemorrhage 04/01/2019 - "Abnormal fibrinogens with either a point mutation in the αC domain or a frameshift mutation resulting in absence of a part of the αC domain are often associated with either thrombotic events or bleeding. " 09/01/1990 - "Dysfibrinogenemias are relatively rare and most are associated with bleeding problems; however, 11% of the abnormal fibrinogens are associated with a clotting tendency. "
3.	Congenital Dysfibrinogenemia 03/01/2022 - "Congenital dysfibrinogenemia is characterized by qualitatively abnormal fibrinogens with resultant blood coagulation dysfunction. " 04/30/1976 - "Modified fibrinogen reveals some similarities to abnormal fibrinogens in congenital dysfibrinogenemia with regard to its functional properties."
4.	Hemangioma (Angioma) 09/02/2017 - "Result: Clinical characteristics of 10 cases (6 male and 4 female) RKHE with KMS were refractory dark red hard hemangioma or ecchymosis, the platelet counts were lower than 30.0×10(9)/L, (15±7)×10(9)/L, coagulation tests were obviously abnormal, fibrinogens were significantly decreased(0.8±0.5)g/L, the fibrin lysates and D-dimer were significantly increased(100±23)mg/L, (10 000±2 200)ng/L, the prothrombin time and activated partial thromboplastin time were prolonged(25.0±2.1)s, (58.0±3.4)s. "
5.	Ecchymosis 09/02/2017 - "Result: Clinical characteristics of 10 cases (6 male and 4 female) RKHE with KMS were refractory dark red hard hemangioma or ecchymosis, the platelet counts were lower than 30.0×10(9)/L, (15±7)×10(9)/L, coagulation tests were obviously abnormal, fibrinogens were significantly decreased(0.8±0.5)g/L, the fibrin lysates and D-dimer were significantly increased(100±23)mg/L, (10 000±2 200)ng/L, the prothrombin time and activated partial thromboplastin time were prolonged(25.0±2.1)s, (58.0±3.4)s. "

Related Drugs and Biologics

1.	Protein S
2.	Protein C
3.	Plasminogen Activators (Plasminogen Activator)
4.	Plasminogen
5.	Fibrinogen (Factor I)
6.	Fibrin
7.	Antithrombin III
8.	fibrin fragment D (D-dimer)